1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Global Growth Factors (Blood and Tissue) Industry

Global Growth Factors (Blood and Tissue) Industry

  • June 2014
  • -
  • Global Industry Analysts
  • -
  • 273 pages

This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 90 companies including many key and niche players such as -

Alseres Pharmaceuticals, Inc.
Amgen, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biogen Idec Inc.
BioMimetic Therapeutics, Inc.

Table Of Contents

Global Growth Factors (Blood and Tissue) Industry



I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
Blood Growth Factors I-3
Erythropoietins I-3
Colony Stimulating Factors I-4
Interferons I-4
Interleukins I-4
Tissue Growth Factors I-4


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW II-1
Growth Factors: A Preface II-1
Burgeoning Global Population Offers Significant Growth
Opportunities II-2
Table 1: Top 25 Countries Worldwide in Terms of Population
(2010 and 2013) (includes corresponding Graph/Chart) II-2
Aging Global Population: Need for New Effective Drugs II-3
Table 2: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-4

Table 3: Over-65 Years Population as a % of Total Population
(2010 and 2020P) (includes corresponding Graph/Chart) II-5

Table 4: Elderly Population (65+ Years) as a % of Total
Population (2000 and 2025) (includes corresponding Graph/Chart) II-5
Increasing Healthcare Spending in Emerging Markets:
Opportunities in Store II-5
Table 5: Healthcare Spending as % of GDP in Select Countries
(2011) (includes corresponding Graph/Chart) II-6
Global Spending on Medicines: A Review II-6
Table 6: Global Medicine Spending (2013): Percentage Share
Breakdown by Region/Country (includes corresponding
Graph/Chart) II-7
Biologics: Rapidly Gaining Ground II-8
Table 7: Global Market for Biologics (2013E) - Percentage
Share Breakdown of Sales by Therapy Area (includes
corresponding Graph/Chart) II-9
Erythropoietin (EPO) Market: An Insight II-9
Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy II-10
CKD Prevalence II-10
Table 8: Number of ESRD Patients in the World (2010-2015)
(includes corresponding Graph/Chart) II-11

Table 9: Worldwide Dialysis Prevalence Rates (Patients per
Million Population) for 2010-2015 (includes corresponding
Graph/Chart) II-11
Cancer Prevalence II-12
Table 10: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and the Caribbean, and Africa (includes corresponding
Graph/Chart) II-12

Table 11: New Cancer Cases in the World by Affected Site
(2012) (in Thousands) (includes corresponding Graph/Chart) II-13
Cancer Prone Sites based on Age II-13
Competition in EPO Market II-13
Leading EPO Drugs Worldwide II-13
Comparison of Erythropoietin-Based Drugs in America and
European Union II-14
Safety and Efficacy Issues Concerning ESAs II-14
Serum Half-Life: A Key Attribute Differentiating ESAs II-14
EPO's Illegal Use in Endurance Sports: A Cause of Concern II-15
Interferons Market: Rising Demand for Specialized Therapies to
Drive Growth II-15
Patent Expiries of Major Interferon Drugs II-16
Biosimilar Beta Interferon Market: EMA Guidelines to Hamper
Investments? II-16
Colony Stimulating Factors (CSFs) Market in Myeloma Patients II-16
Neurotrophic Therapeutics: Recent Advancements and Challenges II-17
Clinical Trial Status of Neurotrophin Therapy for Major
Neurodegenerative Diseases (2012) II-18
Interleukin-17 Market for Psoriasis Treatment: Positive
Opportunities II-18
Anti-IL-6 Pathways for RA Treatment: Favorable Prospects II-18
Blood Growth Factors: Improving Circulation and Mobility in
Peripheral Artery Disease Patients II-19
Wound Management Market and Cellular Growth Factors II-19
Table 12: Global Wound Growth Factors Market (2013):
Percentage Share Breakdown of Sales by Region (includes
corresponding Graph/Chart) II-20
Multiple Sclerosis Drugs Market: Competition Set to Intensify II-20
Interferon-based Drugs for HCV Treatment: An Insight II-21
Patent Expiries Fuel Competition and Sales II-22
Patent Expiries of Biopharmaceuticals in Europe and United
States II-22
Innovative Delivery System Shows Potential for Accelerating
Use of Growth Factors II-23
Cytokines: Vital Growth Propellers for the Future of New Drugs II-23
Brain Derived Neurotrophic Factor (BDNF) Finds Increased
Application II-23
Mimetic Growth Factors - Promising Potential II-23
New Technologies - Challenge to Growth Factors Market II-24
Influence of Neurotrophic Factors on Brain Cell Development II-24
Side Effects - Still a Concern II-24
Combination of Interferons and Ribavirin Develops More Anemia
Cases II-24
Development of Cost Effective Methods - Need of the Hour II-25
hMSC-based Therapies to Drive Need for Growth Factors II-25

2. GROWTH FACTORS - AN OVERVIEW II-26
Blood Growth Factors II-26
Erythropoietins II-26
Types of Erythropoietins II-27
Epoetin II-27
Darbepoetin II-27
Aranesp® II-27
Aranesp Vs. Other EPOs II-27
Recombinant Human EPO (rHuEPO) II-27
Colony Stimulating Factors II-28
Granulocyte-Colony Stimulating Factor II-28
Granulocyte Macrophage-Colony Stimulating Factor II-28
Other Colony Stimulating Factors II-28
Macrophage Colony Stimulating Factor (M-CSF) II-29
Key Functions of M-CSF II-29
Side-Effects of Colony-Stimulating Factors II-29
Interferons II-29
Types of Interferons II-29
Interferon-gamma II-30
1a and 1b: Two Key Biochemical Forms of Interferon-ß II-30
PEG-Intron II-30
Types of Interferons II-30
Interleukins II-31
Types of Interleukins II-31
Tissue Growth Factors II-32
Wound Healing Growth Factors II-32
Neurotrophic Growth Factors II-32
Nerve Growth Factor II-32
Vascular Endothelial Growth Factor (VEGF) II-32
Fibroblast Growth Factor (FGF) II-32
Insulin-Like Growth Factor-I (IGF-I) II-33
Insulin-Like Growth Factor-II (IGF-II) II-33
Tissue Growth Factors: Classification Based on Key Source
and Principal Activity II-33
Platelet - Derived Growth Factors in Wound Healing II-33
Thrombopoietin (TPO) II-33
Growth Factors: Their Mode of Action in Tissue Repair II-34
Angiogenesis: Their Role in Wound Healing II-34
Angiogenesis As an Alternative for Cardiac Stents II-34
Applications of Growth Factors II-35
Growth Factors: Site/Course of Action and Applications II-35

3. RESEARCH STUDIES and CLINICAL TRIALS II-36
Aberrant Regulation of PDGFs and PDGFR in Solid Tumors II-36
Stem Cell Combination Therapy Shows Improvement in Outcomes of
Brain Injury II-36
Cytokine IL-22 Promotes Pathogen Colonization II-36
Amgen Releases Results of Phase III PAVES Study II-36
Amgen Releases Phase 3 Aranesp® (darbepoetin alfa) RED-HF®
Trial Results II-36
FibroGen Releases Data of Phase 2 Hemoglobin Correction Study II-36
Study Shows Therapeutic Potential of Neurotrophins II-37
Study Shows Link between Improved Kidney Transplant Outcomes
and Anemia Correction with EPO II-37
Study Examines Intranasal Delivery of GDF5 to Brain II-37
Bolder Publishes Research Supporting IL-11 Efficacy in
Preventing Kidney Damage in Mice II-37
Study Shows Varying Repair Rates for Growth Factor-based
Treatment of Osseous Defects II-37

4. PRODUCT INNOVATIONS/INTRODUCTIONS II-38
Sandoz Bags Japanese Approval for Biosimilar Filgrastim II-38
Teva Markets Lipegfilgrastim in the UK II-38
Nippon Kayaku Launches TevaGrastim in Japan II-38
Teva Launches Lipegfilgrastim in Germany II-38
SITC Guidelines for Melanoma Treatment Include Proleukin® by
Prometheus Laboratories II-38
Teva Receives EC Approval to Market Lonquex II-38
Genexine's G-CSF Approved for Clinical Phase I by Korean Ministry II-39
Nippon Receives Approval for G-CSF II-39
SYGNIS Discontinues AX 200 Development II-39
First G-CSF Biosimilar Approved in Japan II-39
Dong-A to Launch Phase III Operations of Filgrastim II-39
Dong-A Launches Phase III Operations of DA 3031 II-39
Teva's XM02 Filgrastim Approved by FDA to Treat Neutropenia II-39
FibroGen's FG-3019 Granted Orphan Drug Designation by FDA II-40
Mylan and Biocon Conducting Preclinical Evaluation of
PEGfilgrastim II-40
Aequus BioPharma in Preclinical Evaluation of AQB 101 II-40
Generon Begins Phase II Trials of F627 II-40
BioMimetic Therapeutics Receives Approval to Market GEM 21S in EU II-40

5. RECENT INDUSTRY ACTIVITY II-41
Five Prime Therapeutics Signs Collaboration Agreement with
Bristol-Myers Squibb II-41
Amgen to Halt EPO Manufacturing Operations at Colorado Plant II-41
Regeneron and Bayer Collaborate to Develop Novel AMD Treatment II-41
Amgen Acquires Franchise Rights on Filgrastim from Roche II-41
Maxygen Shareholders Announce Dissolution Approval II-41
Sangamo BioSciences Acquires Ceregene and its Alzhemier's Drug II-41
Astrazeneca and Fibrogen Enter into Strategic Collaboration II-41
Wright Medical Group and BioMimetic Therapeutics to Combine
Businesses II-42
Spectrum Pharmaceuticals In-Licenses G-CSF from Hanmi
Pharmaceuticals II-42
Pfizer Acquires Excaliard Pharmaceuticals II-42
Transgene Biotek to Sell Erythropoietin Product to Tss Export
GmbH II-42
Shire Acquires Advanced BioHealing II-42
Histogenics Takes Over ProChon Biotech II-42
Terumo Americas Holding Buys Harvest Technologies Corporation II-42

6. FOCUS ON SELECT PLAYERS II-43
Alseres Pharmaceuticals, Inc. (USA) II-43
Amgen, Inc. (USA) II-43
Bayer HealthCare Pharmaceuticals, Inc. (USA) II-43
Biogen Idec Inc (USA) II-44
BioMimetic Therapeutics, Inc. (USA) II-44
Biopharm GmbH (Germany) II-44
Bolder Biotechnology, Inc. (USA) II-45
F. Hoffmann-La Roche Ltd (Switzerland) II-45
Chugai Pharmaceutical Co. Ltd. (Japan) II-45
Genentech, Inc. (USA) II-46
FibroGen, Inc. (USA) II-46
Johnson and Johnson (USA) II-46
Janssen Biotech, Inc. (USA) II-46
Lonza Group (Switzerland) II-47
Merck Serono International S.A. (Switzerland) II-47
NsGene A/S (Denmark) II-47
PeproTech, Inc. (USA) II-48
Reliance GeneMedix Plc (UK) II-48
Sangamo BioSciences, Inc. (US) II-48
Sanofi (France) II-49
Shantha Biotechnics (India) II-49
Scil Proteins GmbH (Germany) II-49
Wockhardt Ltd. (India) II-50

7. GLOBAL MARKET PERSPECTIVE II-51
Table 13: World Recent Past, Current and Future Analysis for
Growth Factors (Blood and Tissue) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-51

Table 14: World Historic Review for Growth Factors (Blood and
Tissue) by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) II-52

Table 15: World 15-Year Perspective for Growth Factors (Blood
and Tissue) by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-53

Table 16: World Recent Past, Current and Future Analysis for
Blood Growth Factors by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-54

Table 17: World Historic Review for Blood Growth Factors by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) II-55

Table 18: World 15-Year Perspective for Blood Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-56

Table 19: World Recent Past, Current and Future Analysis for
Blood Growth Factors by Type - Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-57

Table 20: World Historic Review for Blood Growth Factors by
Type - Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) II-58

Table 21: World 15-Year Perspective for Blood Growth Factors
by Type - Percentage Breakdown of Value Sales for
Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-59

Table 22: World Recent Past, Current and Future Analysis for
Erythropoietins by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-60

Table 23: World Historic Review for Erythropoietins by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) II-61

Table 24: World 15-Year Perspective for Erythropoietins by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-62

Table 25: World Recent Past, Current and Future Analysis for
Colony Stimulating Factors by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-63

Table 26: World Historic Review for Colony Stimulating Factors
by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) II-64

Table 27: World 15-Year Perspective for Colony Stimulating
Factors by Geographic Region - Percentage Breakdown of Value
Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of
World Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-65

Table 28: World Recent Past, Current and Future Analysis for
Interferons as Blood Growth Factors by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-66

Table 29: World Historic Review for Interferons as Blood
Growth Factors by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) II-67

Table 30: World 15-Year Perspective for Interferons as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-68

Table 31: World Recent Past, Current and Future Analysis for
Interleukins as Blood Growth Factors by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-69

Table 32: World Historic Review for Interleukins as Blood
Growth Factors by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) II-70

Table 33: World 15-Year Perspective for Interleukins as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-71

Table 34: World Recent Past, Current and Future Analysis for
Tissue Growth Factors by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-72

Table 35: World Historic Review for Tissue Growth Factors by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) II-73

Table 36: World 15-Year Perspective for Tissue Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-74


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Erythropoietin (EPO) Market: Amgen Continues to Dominate III-1
Leading EPO Drugs in the US III-2
Interferon Market: An Insight III-2
HCV Therapy Market III-2
Colony Stimulating Factors (CSF) Market: An Overview III-3
Emerging Competitors in the G-CSF Market III-3
Table 37: US Short Acting Granulocyte Colony Stimulating
Factors (G-CSFs) Market (2014 and 2020): Percentage Share
Breakdown of Volume Sales for HSP Nivestim, Neupogen,
Sandoz EP2006, and TEVA Granix (includes corresponding
Graph/Chart) III-4

Table 38: US Long Acting Granulocyte Colony Stimulating
Factors (G-CSFs) Market (2014 and 2020): Percentage Share
Breakdown of Volume Sales for HSP peg-Filgrastim,
Neulasta, Sandoz LA-EP2006, and TEVA Balugrastim (includes
corresponding Graph/Chart) III-4
US G-CSF New Entrants - Marketing Approval Status (2013) III-5
US Fuels the Long-term Biosimilars Market III-5
Table 39: Pharmaceutical Industry in the US (2013):
Percentage Share Breakdown of Value Sales for Generic and
Non-Generic Segments (includes corresponding Graph/Chart) III-6

Table 40: US Pharmaceuticals Market (2013): Percentage
Share Breakdown of Value Sales by Specialty and
Non-Specialty Segments (includes corresponding Graph/Chart) III-6
CDER: A Regulatory Review Authority for Growth Factors III-6
Product Launches/Approvals/Innovations III-7
Strategic Corporate Developments III-8
Key Players III-9
B.Market Analytics III-14
Table 41: US Recent Past, Current and Future Analysis for
Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-14

Table 42: US Historic Review for Growth Factors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-15

Table 43: US 15-Year Perspective for Growth Factors by Type -
Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-16

2. CANADA III-17
Market Analysis III-17
Table 44: Canadian Recent Past, Current and Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-17

Table 45: Canadian Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) III-18

Table 46: Canadian 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-19

3. JAPAN III-20
A.Market Analysis III-20
Outlook III-20
Erythropoietin Market III-20
Leading EPO Drugs in Japan III-20
HCV Infection: Combination Therapy Dominates III-20
Product Launches III-21
Chugai Pharmaceutical Co. Ltd. - A Key Player III-21
B.Market Analytics III-22
Table 47: Japanese Recent Past, Current and Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-22

Table 48: Japanese Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) III-23

Table 49: Japanese 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-24

4. EUROPE III-25
A.Market Analysis III-25
Outlook III-25
Erythropoietin Market III-25
Leading EPO Drugs in Europe III-25
Biosimilars Market III-25
Table 50: Biosimilar Penetration in Select EU Countries (2013) III-26
Biosimilars Currently Licensed in Europe III-26
Strategic Corporate Developments III-27
Key Players III-28
B.Market Analytics III-31
Table 51: European Recent Past, Current and Future Analysis
for Growth Factors by Geographic Region - France, Germany,
Italy, UK, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) III-31

Table 52: European Historic Review for Growth Factors by
Geographic Region - France, Germany, Italy, UK, Spain, and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) III-32

Table 53: European 15-Year Perspective for Growth Factors by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-33

Table 54: European Recent Past, Current and Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-34

Table 55: European Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) III-35

Table 56: European 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-36

5. ASIA-PACIFIC III-37
Market Analysis III-37
Table 57: Asia-Pacific Recent Past, Current and Future
Analysis for Growth Factors by Geographic Region - China and
Rest of Asia-Pacific Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-37

Table 58: Asia-Pacific Historic Review for Growth Factors by
Geographic Region - China and Rest of Asia-Pacific Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-38

Table 59: Asia-Pacific 15-Year Perspective for Growth
Factors by Geographic Region - Percentage Breakdown of Value
Sales for China and Rest of Asia-Pacific Markets for Years
2006, 2014 and 2020 (includes corresponding Graph/Chart) III-39

Table 60: Asia-Pacific Recent Past, Current and Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-40

Table 61: Asia-Pacific Historic Review for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) III-41

Table 62: Asia-Pacific 15-Year Perspective for Growth
Factors by Type - Percentage Breakdown of Value Sales for
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-42

5a. CHINA III-43
A.Market Analysis III-43
Outlook III-43
Erythropoietin Market III-43
Table 63: Leading Players in the Chinese EPO Market (2013):
Percentage Share Breakdown of Value Sales for 3SBio,
Beijing Sihuan, Harbin Pharma, Nanjin Huaxin Pharma, and
Others (includes corresponding Graph/Chart) III-44
Injectable Interferons: The Only Treatment for HCV Patients III-44
Hepatitis B Market: Smaller Role of Interferons III-44
G-CSF Market: Competitive Landscape III-45
Table 64: G-CSF Market in China (2013): Percentage Share
Breakdown of Revenues by Agent - Filgrastim, Lenograstim,
Molgramostim, Nartograstim, and Others (includes
corresponding Graph/Chart) III-45

Table 65: Leading Manufacturers in the Chinese G-CSF Market
(2013): Percentage Share Breakdown of Revenues for Hangzhou
Jiuyuan, Jiangsu Wuzhong Pharma, Qilu Pharma, Roche, Xiamen
Amoytop Bio, Xiehe Fajio Qilin, and Others (includes
corresponding Graph/Chart) III-45
Biologics Market: An Overview III-46
Table 66: Chinese Biologics Market (2013): Percentage Share
Breakdown of Value Sales by Segment - EPO, G-CSF, Insulin,
Interferon, Interleukin, mAb, Nerve Growth Factors, and
Others (includes corresponding Graph/Chart) III-46
Key Statistical Findings III-46
Interleukins Market III-46
Table 67: Interleukins Market in China (2013): Percentage
Share Breakdown of Value Sales by Type - Interleukin-11
and Interleukin-2 (includes corresponding Graph/Chart) III-46

Table 68: Leading Players in the Chinese Interleukins
Market (2013): Percentage Share Breakdown of Value Sales
for E China Pharm, Four Rings, QG Pharm, Qilu Pharm, SL
Pharm, and Others (includes corresponding Graph/Chart) III-47
Interferons Market III-47
Table 69: Interferon Market in China (2013): Percentage
Share Breakdown of Value Sales by Type of Interferon
(includes corresponding Graph/Chart) III-47

Table 70: Leading Players in the Chinese Interferons
Market (2013): Percentage Share Breakdown of Value Sales
for Hualida Bio, Huaxin Bio, Merck, Roche, Sinovac,
Tri-Prime Gene, and Others (includes corresponding
Graph/Chart) III-47
B.Market Analytics III-48
Table 71: Chinese Recent Past, Current and Future Analysis for
Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-48

Table 72: Chinese Historic Review for Growth Factors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-49

Table 73: Chinese 15-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-50

5b. REST OF ASIA-PACIFIC III-51
A.Market Analysis III-51
Outlook III-51
India III-51
Biopharmaceutical Drugs Market: Promising Opportunities III-51
Erythropoietins III-52
G-CSF Market III-52
Interferons III-52
Strategic Corporate Developments III-53
Key Players III-53
B.Market Analytics III-54
Table 74: Rest of Asia-Pacific Recent Past, Current and Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-54

Table 75: Rest of Asia-Pacific Historic Review for Growth
Factors by Type - Blood Growth Factors (Erythropoietins,
Colony Stimulating Factors, Interferons and Interleukins)
and Tissue Growth Factors Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) III-55

Table 76: Rest of Asia-Pacific 15-Year Perspective for
Growth Factors by Type - Percentage Breakdown of Value Sales
for Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-56

6. REST OF WORLD III-57
A.Market Analysis III-57
Outlook III-57
Brazil III-57
HCV Therapy Market: Interferons Widely in Use III-57
B.Market Analytics III-58
Table 77: Rest of World Recent Past, Current and Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-58

Table 78: Rest of World Historic Review for Growth Factors
by Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) III-59

Table 79: Rest of World 15-Year Perspective for Growth
Factors by Type - Percentage Breakdown of Value Sales for
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-60


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 90 (including Divisions/Subsidiaries - 95)

The United States (42)
Japan (8)
Europe (19)
- France (1)
- Germany (8)
- The United Kingdom (1)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (24)
Middle East (2)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • August 2016
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable ...

Bioprinting: Technologies and Global Markets

Bioprinting: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Understand market dynamics of bioprinting technologies, applications, and end-user industries. - Assess specific bioprinting-related industries, including 3-D cell culture; bioinks; ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.